Obsidian Therapeutics grants CFO 165K stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Obsidian Therapeutics, Inc. (OBX) Chief Financial Officer Julie B. Feder received an option award covering 164,790 shares of common stock on August 3, 2026, with a $12-per-share exercise price and an August 2, 2036 expiration date. The option vests and becomes exercisable in 16 equal quarterly installments, beginning January 12, 2027; the second installment is February 3, 2027, with the remaining installments each quarter thereafter, subject to Feder’s continued service on each vesting date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 164,790 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vesting on January 12, 2027, the second installment vesting on February 3, 2027, and the remaining installments vesting each quarter thereafter, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
quarterly installments technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option award did Obsidian Therapeutics (OBX) CFO Julie B. Feder receive?
When do Julie B. Feder’s OBX options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.